Jaroslaw K. S.
- Country
- Poland
- Department
- Oncology Department with Chemotherapy Sub-Division
Research Overview
- A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
- A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 483 of 752 partner sites.
Specializations
Non-Small Cell Lung Cancer
The investigator is strongly involved in clinical research on non-small cell lung cancer, with interest across newly diagnosed, locally advanced, metastatic, unresectable, and resected disease. The portfolio includes biomarker-defined populations such as EGFR-mutated, ALK-positive, KRAS G12C-mutated, HER2-altered, MET-driven, and PD-L1-selected disease.
- Metastatic NSCLC
- Resectable and adjuvant NSCLC
- Biomarker-selected targeted therapy
- Immunotherapy combinations
Research activity also extends to squamous and non-squamous histologies, with a clear focus on treatment strategies that refine disease control in advanced thoracic oncology.
Small Cell Lung Cancer
The investigator is active in studies of small cell lung cancer, including both extensive-stage and limited-stage disease. This area includes work on first-line treatment settings and maintenance approaches in aggressive lung cancer subtypes.
- Extensive-stage SCLC
- Limited-stage SCLC
- First-line treatment strategies
- Maintenance immunotherapy
The therapeutic emphasis is on improving outcomes in rapidly progressive disease through novel systemic approaches and combination regimens.
Pulmonary Fibrosis and Chronic Lung Disease
Clinical research also covers idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, reflecting interest in fibrotic lung disorders beyond oncology. These studies address respiratory symptoms and lung function in chronic interstitial lung disease.
- Idiopathic pulmonary fibrosis
- Progressive pulmonary fibrosis
- Lung function preservation
- Chronic cough
This portfolio includes therapeutic investigation in symptom control and disease modification within non-malignant respiratory medicine.
Pleural Mesothelioma and Thoracic Malignancies
The investigator participates in research on unresectable pleural mesothelioma, adding another thoracic cancer domain to the clinical profile. This area complements the broader lung cancer focus and reflects engagement with difficult-to-treat pleural disease.
- Pleural mesothelioma
- Unresectable thoracic malignancy
- Combination systemic therapy
- Survival-focused treatment development
The therapeutic interest centers on advanced thoracic oncology options for patients with limited standard treatment pathways.
Genitourinary and Solid Tumor Oncology
Additional research involvement includes urothelial carcinoma of the urinary tract and broader solid tumors, indicating participation in oncology programs beyond the respiratory system. These studies broaden the therapeutic scope to include advanced malignancies with unmet clinical need.
- Urothelial carcinoma
- Advanced solid tumors
- Pan-tumor oncology
- Targeted and immune-based therapy
The research landscape includes treatment development for malignancies requiring more precise systemic options in later-line and advanced settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.